Desloratadine for the Relief of Nasal and Non-nasal Allergy Symptoms: An Observational Study.
INTRODUCTION: The rates of allergic rhinitis, allergic asthma, and atopic eczema range from 6% to 16% globally. Second-generation antihistamines have been shown to be safe and effective for the treatment of symptoms of allergic disease. This study investigated the efficacy and safety of desloratadine, a nonsedating second-generation antihistamine, in the treatment of common allergy symptoms. METHODS: In this open-label, uncontrolled, non-randomized, observational study, subjects (N = 973) with allergy symptoms were given desloratadine 5 mg daily for 3 weeks. Nasal, ocular, and dermal symptom severity was rated as asymptomatic, mild, moderate, or severe; changes in the percentage of subjects in each severity category were assessed. Overall efficacy and tolerability of desloratadine treatment were evaluated separately by physicians and subjects. RESULTS: Allergic rhinitis was the most frequent diagnosis, occurring in 59.0% of subjects. Approximately 40% of subjects had received previous treatment with other antihistamines, systemic/topical glucocorticosteroids, or beta-sympathicomimetics. Slightly more than half of subjects received concomitant medication during the study; 263 (53.0%) of those used intranasal steroids. A significant reduction in severity scores was observed in all symptom subgroups (P < 0.001). Desloratadine efficacy was judged to be excellent or good by 90.2% of physicians and 88.6% of subjects; 82.5% of investigators and 80.9% of subjects considered it more effective than previous therapy. The tolerability of desloratadine was rated excellent or good by 97.0% of both groups. Thirty-one subjects (3.2%) experienced adverse events. CONCLUSIONS: In an open-label, uncontrolled, non-randomized, observational study allergy symptoms improved significantly in subjects treated with desloratadine.
Aberer
Werner
W
Department of Environmental Dermatology, Medical University of Graz Graz, Austria.
Br J Dermatol. 1997 Feb;136(2):197-201
9068731
Allergy. 2007 Apr;62(4):359-66
17362245
JAMA. 2002 Jan 16;287(3):337-44
11790213
Allergy. 2001 Nov;56(11):1077-80
11703222
Allergy. 2008 Apr;63 Suppl 86:8-160
18331513
Ann Allergy Asthma Immunol. 2006 Feb;96(2):363-8
16498861
J Allergy Clin Immunol. 2003 Jul;112(1):15-22
12847474
Nature. 1999 Nov 25;402(6760 Suppl):B2-4
10586888
J Am Acad Dermatol. 2003 Apr;48(4):535-41
12664016
Int J Dermatol. 2001 Jan;40(1):72-6
11277962
Allergy. 2006 Mar;61(3):316-20
16436140
J Eur Acad Dermatol Venereol. 2008 Jan;22(1):36-40
18181971
Allergy. 2007 Nov;62(11):1331-4
17521311
Ann Allergy Asthma Immunol. 2007 Jul;99(1):29-33
17650826
Ann Allergy Asthma Immunol. 1998 Nov;81(5 Pt 2):478-518
9860027
Ann Allergy Asthma Immunol. 2002 Nov;89(5):485-91
12452207
Br J Dermatol. 2006 Feb;154(2):294-8
16433799
Curr Med Res Opin. 2004 Mar;20(3):305-17
15025839
Trends Immunol. 2002 May;23(5):255-63
12102747
Drug Saf. 2005;28(12):1101-18
16329713
Ann Allergy Asthma Immunol. 2006 Mar;96(3):460-5
16597081
Allergy. 2001;56 Suppl 65:14-20
11243500
J Allergy Clin Immunol. 2003 Mar;111(3):617-22
12642846
Am J Clin Dermatol. 2007;8(1):37-42
17298105